Pursuing the curative blueprint for early myeloma
Pursuing the curative blueprint for early myeloma
复制标题
DOI：
10.1182/blood-2013-01-481291
复制
发表时间：
2013-07-25
期刊：
影响因子：
20.3
通讯作者：
Landgren, Ola
中科院分区：
文献类型：
--
作者：
Roschewski, Mark;Korde, Neha;Landgren, Ola
多发性骨髓瘤（MM）的治疗理念争论的相对优点是实现最大程度的缓解（“治愈”主义）与顺序提供抗骨髓瘤药物（“控制”主义）。在本文中，我们强调了在现代患者选择策略、MM发病机制的新生物学见解、安全性提高的药物以及新兴的分子和成像工具的背景下，每种学说的相关优势。最重要的基本问题仍未得到解答，在我们寻求治愈这种毁灭性疾病的方法时，需要集中精力进行深入研究。
Treatment philosophies in multiple myeloma (MM) debate the relative merits of achieving the deepest possible remissions ("curative" doctrine) vs sequential delivery of antimyeloma agents ("control" doctrine). In this paper, we highlight the relevant strengths of each doctrine in the context of modern patient selection strategies, fresh biological insights on MM pathogenesis, agents with improved safety profiles, and emerging molecular and imaging tools. Paramount fundamental questions remain unanswered that require an intense research focus as we pursue a cure for this devastating disease.